ONTAK (denileukin difitox, DAB389IL-2)
#33
Approved small_molecule completed
Quick answer
ONTAK (denileukin difitox, DAB389IL-2) for Lymphoma, T-Cell, Cutaneous is a Approved program (small_molecule) at LIGAND PHARMACEUTICALS INC with 1 ClinicalTrials.gov record(s).
Program details
- Company
- LIGAND PHARMACEUTICALS INC
- Indication
- Lymphoma, T-Cell, Cutaneous
- Phase
- Approved
- Modality
- small_molecule
- Status
- completed